Nuevos anticoagulantes orales.

Author
Berkovits, Alejandro; Departamento de Hematología-Oncología, Sección Hemostasia-Trombosis, Escuela de Medicina, Pontificia Universidad Católica de Chile

Aizman, Andrés; Departamento de Medicina Interna, Escuela deMedicina, PUC

Zúñiga, Pamela; Departamento de Hematología-Oncología, Sección Hemostasia-Trombosis, Escuela de Medicina, Pontificia Universidad Católica de Chile

Pereira, Jaime; Departamento de Hematología-Oncología, Sección Hemostasia-Trombosis, Escuela de Medicina, Pontificia Universidad Católica de Chile

Mezzano, Diego; Departamento de Hematología-Oncología, Sección Hemostasia-Trombosis, Escuela de Medicina, Pontificia Universidad Católica de Chile

Full text
http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/1193
Abstract
NEW ORAL ANTICOAGULANT DRUGS Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.   
Metadata
Show full item record